{"id":"W4380053056","doi":"10.1210/jcemcr/luad058","title":"Treatment of Homozygous Familial Hypercholesterolemia With ANGPTL3 Inhibitor, Evinacumab","year":2023,"lang":"en","type":"article","venue":"JCEM Case Reports","topic":"Lipid metabolism and disorders","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hospital for Sick Children; University of Toronto; SickKids Foundation; Western University","funders":"Amryt Pharma; Ultragenyx Pharmaceutical; Canadian Institutes of Health Research; Esperion Therapeutics; Regeneron Pharmaceuticals; Academic Medical Organization of Southwestern Ontario; Sanofi; HLS Therapeutics; Amgen; Pfizer; Heart and Stroke Foundation of Canada","keywords":"Ezetimibe; Familial hypercholesterolemia; Medicine; LDL apheresis; PCSK9; Asymptomatic; Apheresis; Internal medicine; Adverse effect; Compound heterozygosity; Statin; LDL receptor; Gastroenterology; Cholesterol; Pediatrics; Lipoprotein; Mutation; Biochemistry","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007924301,0.0001835685,0.0002854306,0.0001401042,0.0003251899,0.0001416522,0.0001686166,0.0003504795,0.0004528843],"category_scores_gemma":[0.0001959353,0.00005051641,0.0001747268,0.0001011708,0.0001522693,0.00009620272,0.0001131376,0.000516184,0.0001756477],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006053255,"about_ca_system_score_gemma":0.0002901916,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003061937,"about_ca_topic_score_gemma":0.006899194,"domain_scores_codex":[0.9999471,0.000008388285,0.000005909763,0.000009605373,0.00001159214,0.00001738181],"domain_scores_gemma":[0.9999361,0.000008530548,0.00001145009,0.000003147559,0.000006412581,0.00003429467],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"case_report","study_design_gemma":"case_report","study_design_scores_codex":[0.004585103,0.001413697,0.1417483,0.0008081881,0.0004115989,0.3271951,0.0006228088,0.001526588,0.180637,0.001857076,0.02414018,0.3150544],"study_design_scores_gemma":[0.00115985,0.00533871,0.3017961,0.0003405004,0.0004111129,0.5454583,0.0003530269,0.005868672,0.05420854,0.001421345,0.08355723,0.00008662482],"study_design_candidate":"case_report","study_design_consensus":"case_report","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9663991,0.01855543,0.002650739,0.002444407,0.0001942745,0.00006485954,0.0002063415,0.0002507202,0.009234133],"genre_scores_gemma":[0.994166,0.002193104,0.000996789,0.0007822218,0.00006951624,0.00001516459,0.0002205239,0.00001499412,0.001541643],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003061937,"threshold_uncertainty_score":0.006088257,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01979929793660709,"score_gpt":0.2784904564975966,"score_spread":0.2586911585609895,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}